These findings expand the understanding of IKAROS from a DNA-binding repressor to a multifunctional architectural factor and suggest that restoring IKAROS-like chromatin states, or targeting their aberrant counterparts, may provide a tractable strategy for treatment of high-risk B-ALL. Here, IKZF1 is linked to acute lymphoblastic leukemia.